The PASTEUR Act establishes a subscription-style model for the U.S. government to secure a reliable supply of novel antimicrobials to address the most serious and life-threatening infections and combat the threat of antimicrobial resistance (AMR). By delinking payment from sales volume, PASTEUR ensures that payment reflects the value of antimicrobials to public health and supports their judicious use.
Since 2013, the FDA approved 8 antibiotics from small companies. Today, every single company behind those antibiotics has either gone…
Read MoreAntibiotic-resistant infections contributed to nearly 5 million deaths in 2019. In 2020, hospital-onset drug-resistant infections and deaths jumped 15% as…
Read MoreGlobally, drug-resistant bacterial infections killed over 1.2 million people and played a role in 4.95 million deaths in 2019. By…
Read MoreWhat is the superbug crisis? Superbugs are bacteria or fungi that are resistant to antibiotics and other treatments, a process…
Read More